MPR- Medical Professionals Reference

Medical Societies Condemn CDC Update Suggesting Vaccine-Autism Link According to the US Department of Health and Human Services, research plans to investigate all the possible causes of autism are in the works.

Drawing backlash from multiple medical organizations, the CDC website has been updated to suggest a vaccine-autism link. In his January confirmation hearing RFK Jr said he would not impose his personal antivax views. ➡️ www.empr.com/news/medical...

Fibromyalgia Treatment Tonmya Now Available Tonmya is a once-daily sublingual tablet of cyclobenzaprine HCI taken at bedtime for the treatment of fibromyalgia.

Tonmya (cyclobenzaprine HCl sublingual tablets) is now commercially available, the first new FDA-approved fibromyalgia treatment in over 15 years. #Fibromyalgia #DrugApprovals #NewDrug www.empr.com/news/fibromy...

October 2025 Drug Approvals: Our at-a-glance essential prescribing update. ➡️ www.empr.com/news/october...

Komzifti Approved for Adults With R/R NPM1-Mutated AML The approval was based on data from the single-arm, open-label phase 2 KOMET-001 trial, which evaluated ziftomenib, a menin inhibitor, in adults with R/R AML with an NPM1 mutation.

The FDA has fully approved Komzifti (ziftomenib), the first and only once-daily oral menin inhibitor, for adults with R/R NPM1-mutated AML. www.empr.com/news/komzift...

Get yourself up to date on Lynkuet — a treatment approved for vasomotor symptoms due to menopause — with our InsightRx interview with trial investigator Dr JoAnn Pinkerton. www.empr.com/news/lynkuet...

Dosing Error Goes Unrecognized Leading to Serious Patient Harm Over the course of the patient's treatment, there were opportunities to recognize the error and prevent the patient's catastrophic results.

Law feature: This month's case resulted in a jury finding in favor of the patient to the tune of $40 million dollars and apportioned the pharmacist's fault at 2%. www.empr.com/features/dos...

Lynkuet® (elinzanetant) for the Treatment of Vasomotor Symptoms Due to Menopause JoAnn Pinkerton MD, discusses Lynkuet® (elinzanetant), a new FDA-approved treatment for moderate to severe vasomotor symptoms due to menopause. Dr

Lynkuet was recently approved to treat vasomotor symptoms due to menopause, hear all about it in our interview with one of the trial investigators in our latest InsightRx! www.empr.com/news/lynkuet...

Current evidence for the use of leucovorin to treat autism symptoms is mainly limited to small studies and case reports in children with CFD.
www.empr.com/news/aap-cur...

From ACR 2025: biologic disease-modifying antirheumatic drugs (DMARDs) appear to be tied to worse COVID-19 outcomes than conventional DMARDs. www.empr.com/reports/biol...

This Class II Neutrogena recall involves 1312 cases of the 50-count, 25-pack towelettes. www.empr.com/news/neutrog...

Brekiya Now Available for Migraine, Cluster Headache Treatment Brekiya is available with prescription exclusively through Walgreens Specialty Pharmacy and Sterling Specialty Pharmacy.

Prefilled single-dose autoinjector now available for treatment of migraine and cluster headache. www.empr.com/news/brekiya...

MPR Weekly Dose Podcast #254 Label changes for tranexamic acid; new approval for Tezspire; psychedelic gains Breakthrough Tx for depression; oral semaglutide approved to reduce MACE risk in T2DM; Gazyva approved for lupus.

🎧 Latest MPR Pod out now!
🔹 Label changes for tranexamic acid;
🔸 New approval for Tezspire;
🔹 Psychedelic gains Breakthrough Tx status for depression;
🔸 Oral semaglutide approved to reduce MACE risk in T2DM; and
🔹 Gazyva approved for lupus nephritis.
www.empr.com/news/mpr-wee...

Findings showed the study did not meet its primary endpoint of preventing CMV infection in seronegative participants. www.empr.com/news/moderna...

FDA and Kenvue Say No Autism Link to Tylenol Use During Pregnancy The maker of Tylenol is urging the FDA to reject autism warning requests for the drug's use in pregnancy.

Tylenol maker urges regulators to not add autism warning to label citing a lack of scientific evidence. www.empr.com/news/fda-and...

Drug combo gets Priority Review for possible adjuvant treatment in patients with muscle-invasive bladder cancer. www.empr.com/news/enfortu...

FDA: Administration Mix-Ups Prompt Tranexamic Acid Injection Label Changes The alert was issued after medication error cases of tranexamic acid injection administered neuraxially instead of the intended local anesthetic were reported.

There have been continued reports of tranexamic acid being erroneously administered resulting in serious harm and prompting this label change. www.empr.com/news/fda-adm...

Participants in a social anxiety treatment trial were tasked with delivering a 5 minutes speech with 2 minutes notice. The results did not match the primary endpoint. www.empr.com/news/negativ...

From 2005 to 2024, an estimated 3,112 pickleball-related ocular injuries occurred, with 1,262 injuries occurring in 2024 alone.
www.empr.com/news/pickleb...

A psychedelic nasal spray has been designated a Breakthrough therapy by the FDA. www.empr.com/news/intrana...

Jascayd was recently approved to treat idiopathic pulmonary fibrosis, we spoke to one of the trial investigators it in our latest InsightRx. www.empr.com/news/jascayd...

📢 Latest MPR Podcast out now!
🔹 New treatment approved for bipolar I disorder;
🔸 Rinvoq IBD indications updated;
🔴 Blood-based test for early detection of amyloid pathology; and
💊 Oral GLP-1 treatment continues to show promise in T2D.
www.empr.com/news/mpr-wee...

FDA Extends Review for Tividenofusp Alfa for Hunter Syndrome The extension was necessary to review updated clinical pharmacology information submitted by Denali.

Review period extended for novel Hunter syndrome treatment. www.empr.com/news/fda-ext...

Jury Sides With Plaintiff's Medical Expert in Unanimous $60 Million Verdict This month’s case resulted in a large monetary verdict against the physician, possibly a record-breaking sum in the New York country where it took place.

Law Feature: Jury awards enormous sum to patient who suffered devastating consequences from medical procedure. www.empr.com/features/jur...

Rhapsido was recently approved for chronic spontaneous urticaria, find out all about it from one of the clinical trial investigators on MPR's InsightRx. www.empr.com/news/rhapsid...

Immunization schedule changes approved for COVID-19 vaccines. www.empr.com/news/cdc-app...

FDA Denies Approval of Brexpiprazole Plus Sertraline for PTSD Brexpiprazole is an atypical antipsychotic approved under the brand name Rexulti for the treatment of MDD as an adjunctive therapy to antidepressants, schizophrenia, and agitation associated with deme...

The FDA said the application could not be approved due to a lack of substantial efficacy from the submitted studies.
www.empr.com/news/fda-den...

MPR Weekly Dose Podcast #251 New treatment approved for primary humoral immunodeficiency; eyedrops now available to improve near vision; Tremfya approval expanded to include pediatric

📢 MPR Pod out now!
🔸 New Tx approved for primary humoral immunodeficiency;
👀 Eyedrops available to improve near vision;
👦 Tremfya expanded to include pediatric patients;
🔹 FDA Fast Tracks treatments for methamphetamine intoxication, Alzheimer disease.
www.empr.com/news/mpr-wee...

Potential treatment for autosomal dominant polycystic kidney disease gains Fast Track status. www.empr.com/news/fda-fas...

Rhapsido Approved for Adults With Chronic Spontaneous Urticaria Rhapsido is supplied as a 25mg tablet.

Oral option approved to treat chronic spontaneous urticaria. www.empr.com/news/rhapsid...

Vizz Eyedrops Now Available to Improve Near Vision in Adults Vizz eye drops contain a cholinergic muscarinic agonist that causes contraction of the iris sphincter muscle, resulting in a pinhole effect that extends focus depth to improve vision in presbyopia.

Recently approved eye drop to treat presbyopia now available. www.empr.com/news/vizz-ey...